InspireMD, Inc. (NSPR): Results of Operations and Financial Condition
InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - Miami, FL — August 17, 2026 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), develope
How this was made
The 30-second read
Why it matters
The most tradable elements are the recall-driven financial effects (U.S. revenue negative for the quarter, inventory impairment, revenue credits), the cost-savings actions targeting about $9M annual savings, and the stated expectation of FDA decisions later in 2026 alongside an anticipated FDA submission before year-end for CGuard Prime 135 cm delivery system design changes.
Market read
This is a company-specific regulatory and commercialization update with quantified financial impacts from the voluntary recall and a cash balance change, plus clinical progress that may influence expectations for FDA timing.
What to watch
Cash fell to $30.4M from $54.2M at year-end, so traders may underweight financing risk relative to the clinical and FDA timeline.
Background
SEC 8-K Item 2.02 with Exhibit 99.1 covering InspireMD’s Q2 2026 financial results and key operational updates for its CGuard Prime and SwitchGuard programs.
Ticker impact
InspireMD reported Q2 2026 revenue of $1.771M, including $734K recall-related credits and a $612K inventory impairment, plus ongoing FDA dialogue and planned re-launch.
Near-term downside risk from lower U.S. revenue and reduced cash, partially offset by progress on design changes and continued expectation of FDA decisions later in 2026.
The article discloses concrete financial impacts from the voluntary recall (credits and impairment), a material cash decline from year-end, and specific operational milestones (design changes validation, CGUARDIANS II 30-day outcomes, CGUARDIANS III enrollment) tied to anticipated FDA decisions later this year.
Market effects
Adds datapoints for carotid stent and neuroprotection device developers on how voluntary recalls can flow through revenue and gross margin.
Highlights continued international demand growth (+21% in Q2) despite U.S. disruption.
Limited broader market impact; primarily company-specific regulatory and commercialization timing risk.
Counterpoint
Despite U.S. revenue weakness, international growth and positive 30-day CGUARDIANS II outcomes suggest the core platform may still be gaining traction outside the recall window.
Key entities
- issuerInspireMD, Inc.
Developer of the CGuard Prime carotid stent system and SwitchGuard neuroprotection system; subject of the 8-K.
- productCGuard Prime 135 cm delivery system
Voluntarily recalled in May; design changes are undergoing validation and performance testing ahead of FDA submission.
- productCGuard Prime 80 cm implant for TCAR procedures
Pending regulatory submissions; company expects FDA decisions later in 2026.
- clinical_trialCGUARDIANS II
Company reported 30-day outcomes for the CGuard Prime 80 cm implant in TCAR procedures.
- clinical_trialCGUARDIANS III
Company commenced patient enrollment for SwitchGuard NPS with the CGuard Prime 80 cm platform in TCAR procedures.
